{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:16:28Z","timestamp":1774084588284,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6125,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1093\/annonc\/mdg157","type":"journal-article","created":{"date-parts":[[2003,3,20]],"date-time":"2003-03-20T23:19:48Z","timestamp":1048202388000},"page":"599-602","source":"Crossref","is-referenced-by-count":139,"title":["Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972"],"prefix":"10.1016","volume":"14","author":[{"given":"M.J.","family":"van den Bent","sequence":"first","affiliation":[]},{"given":"O.","family":"Chinot","sequence":"additional","affiliation":[]},{"given":"W.","family":"Boogerd","sequence":"additional","affiliation":[]},{"given":"J.","family":"Bravo Marques","sequence":"additional","affiliation":[]},{"given":"M.J.B.","family":"Taphoorn","sequence":"additional","affiliation":[]},{"given":"J.M.","family":"Kros","sequence":"additional","affiliation":[]},{"given":"C.C.D.","family":"van der Rijt","sequence":"additional","affiliation":[]},{"given":"C.J.","family":"Vecht","sequence":"additional","affiliation":[]},{"given":"N.","family":"De Beule","sequence":"additional","affiliation":[]},{"given":"B.","family":"Baron","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg157_bb0010","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.1994.12.10.2013","article-title":"Chemotherapy for anaplastic oligodendroglioma","volume":"12","author":"Cairncross","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg157_bb0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1212\/WNL.53.5.1141","article-title":"Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggressive oligodendroglioma","volume":"53","author":"Paleologos","year":"1999","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdg157_bb0020","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1212\/WNL.51.4.1140","article-title":"Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy","volume":"51","author":"van den Bent","year":"1998","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdg157_bb0025","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/00006123-199811000-00035","article-title":"PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas","volume":"43","author":"Soffietti","year":"1998","journal-title":"Neurosurgery"},{"key":"10.1093\/annonc\/mdg157_bb0030","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg157_bb0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdg157_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdg157_bb0045","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg157_bb0050","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.57.2.340","article-title":"Temozolomide chemotherapy in recurrent oligodendroglioma","volume":"57","author":"van den Bent","year":"2001","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdg157_bb0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1008336732273","article-title":"Temozolomide as a second line systemic regimen in recurrent high-grade glioma: a phase II study","volume":"12","author":"Brandes","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg157_bb0060","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2001.19.9.2449","article-title":"Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy","volume":"19","author":"Chinot","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg157_bb0065","article-title":"Resistance of anaplastic oligodendroglioma (AO) to procarbazine\u2013CCNU\u2013vincristine (PCV) is correlated to a glioblastoma","volume":"20","author":"Chinot","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg157_bb0070","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W","article-title":"Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas","volume":"79","author":"Coons","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg157_bb0075","first-page":"839","article-title":"Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis","volume":"7","author":"Ino","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdg157_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11187","article-title":"Chromosomal anomalies in oligodendroglial tumors are correlated to clinical features","author":"van den Bent","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg157_bb0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3171\/jns.1996.85.4.0597","article-title":"Salvage chemotherapy for oligodendroglioma","volume":"85","author":"Peterson","year":"1996","journal-title":"J Neurosurg"},{"key":"10.1093\/annonc\/mdg157_bb0090","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1200\/JCO.1997.15.12.3427","article-title":"Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas","volume":"15","author":"Chamberlain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg157_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1019608404378","article-title":"Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas","volume":"59","author":"Chamberlain","year":"2002","journal-title":"J Neuro-Oncology"},{"key":"10.1093\/annonc\/mdg157_bb0100","first-page":"62","article-title":"Salvage chemotherapy with carboplatin for recurrent oligodendroglial tumors","volume":"3","author":"Nobile","year":"2001","journal-title":"Neuro-Oncology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419640937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419640937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/4\/599\/408094\/mdg157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:14:05Z","timestamp":1582251245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419640937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["S0923753419640937"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg157","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}